FibroGen Valuation
Is FGEN * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of FGEN * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate FGEN *'s fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate FGEN *'s fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for FGEN *?
Other financial metrics that can be useful for relative valuation.
What is FGEN *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$104.95m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.8x |
Enterprise Value/EBITDA | -0.6x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does FGEN *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 11.4x | ||
ELUT Elutia | 4.7x | 35.9% | US$97.7m |
6704 Gwo Xi Stem Cell Applied Technology | 25.9x | n/a | NT$3.7b |
TNG Transgene | 13.9x | 23.6% | €110.2m |
ALERS Eurobio Scientific Société anonyme | 1.1x | 6.1% | €141.6m |
FGEN * FibroGen | 0.6x | 2.0% | Mex$104.9m |
Price-To-Sales vs Peers: FGEN * is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (11.4x).
Price to Earnings Ratio vs Industry
How does FGEN *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Sales vs Industry: FGEN * is good value based on its Price-To-Sales Ratio (0.6x) compared to the Global Biotechs industry average (9.9x).
Price to Sales Ratio vs Fair Ratio
What is FGEN *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 0.6x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate FGEN *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$22.00 | Mex$29.05 +32.1% | 14.3% | Mex$33.21 | Mex$24.90 | n/a | 2 |
Jun ’25 | n/a | Mex$29.05 0% | 14.3% | Mex$33.21 | Mex$24.90 | n/a | 2 |
May ’25 | n/a | Mex$28.95 0% | 14.3% | Mex$33.09 | Mex$24.82 | n/a | 2 |
Apr ’25 | n/a | Mex$21.37 0% | 60.0% | Mex$34.19 | Mex$8.55 | n/a | 2 |
Mar ’25 | Mex$35.00 | Mex$21.37 -38.9% | 60.0% | Mex$34.19 | Mex$8.55 | n/a | 2 |
Feb ’25 | Mex$29.00 | Mex$21.50 -25.9% | 60.0% | Mex$34.39 | Mex$8.60 | n/a | 2 |
Jan ’25 | n/a | Mex$21.50 0% | 60.0% | Mex$34.39 | Mex$8.60 | n/a | 2 |
Dec ’24 | n/a | Mex$21.50 0% | 60.0% | Mex$34.39 | Mex$8.60 | n/a | 2 |
Nov ’24 | n/a | Mex$182.73 0% | 137.0% | Mex$616.46 | Mex$35.23 | n/a | 4 |
Oct ’24 | Mex$15.08 | Mex$182.73 +1,111.8% | 137.0% | Mex$616.46 | Mex$35.23 | n/a | 4 |
Sep ’24 | Mex$20.20 | Mex$178.61 +784.2% | 121.1% | Mex$595.36 | Mex$34.02 | n/a | 5 |
Aug ’24 | n/a | Mex$214.13 0% | 94.5% | Mex$599.57 | Mex$34.26 | n/a | 6 |
Jul ’24 | n/a | Mex$214.13 0% | 94.5% | Mex$599.57 | Mex$34.26 | n/a | 6 |
Jun ’24 | n/a | Mex$459.31 0% | 25.3% | Mex$614.37 | Mex$280.85 | n/a | 6 |
May ’24 | n/a | Mex$454.41 0% | 25.2% | Mex$640.44 | Mex$292.77 | n/a | 6 |
Apr ’24 | n/a | Mex$454.41 0% | 25.2% | Mex$640.44 | Mex$292.77 | n/a | 6 |
Mar ’24 | n/a | Mex$454.41 0% | 25.2% | Mex$640.44 | Mex$292.77 | Mex$35.00 | 6 |
Feb ’24 | Mex$405.00 | Mex$400.73 -1.1% | 39.7% | Mex$657.45 | Mex$169.06 | Mex$29.00 | 6 |
Jan ’24 | n/a | Mex$312.35 0% | 29.3% | Mex$454.68 | Mex$177.92 | n/a | 5 |
Dec ’23 | n/a | Mex$320.35 0% | 28.8% | Mex$449.28 | Mex$175.80 | n/a | 5 |
Nov ’23 | Mex$350.50 | Mex$299.14 -14.7% | 42.4% | Mex$498.57 | Mex$159.54 | n/a | 5 |
Oct ’23 | n/a | Mex$291.67 0% | 42.3% | Mex$506.37 | Mex$162.04 | Mex$15.08 | 5 |
Sep ’23 | n/a | Mex$291.67 0% | 42.3% | Mex$506.37 | Mex$162.04 | Mex$20.20 | 5 |
Aug ’23 | Mex$251.00 | Mex$262.51 +4.6% | 48.5% | Mex$497.18 | Mex$159.10 | n/a | 5 |
Jul ’23 | n/a | Mex$262.51 0% | 48.5% | Mex$497.18 | Mex$159.10 | n/a | 5 |
Jun ’23 | Mex$181.00 | Mex$262.51 +45.0% | 48.5% | Mex$497.18 | Mex$159.10 | n/a | 5 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.